Secondary hyperparathyroidism (SHPT) occurs when the parathyroid glands become enlarged and release too much PTH, causing a high blood level of PTH. Parathyroid hormone controls the level of calcium is in the blood and within bones. Secondary hyperparathyroidism can cause bone disease. It can also cause calcium to build up in tissues and organs such as the heart and blood vessels. The bones are in a constant state of change. There are cells that build new bone and cells that remove old bone. This process is known as “bone turnover.” If one has secondary hyperparathyroidism, bone turnover is high. This means that the cells that remove bone are working more quickly than the cells that build new bone, causing your bones to become weak and brittle. This can increase your chances of having bone pain and fractures.
DelveInsight's "Secondary Hyperparathyroidism Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the disease, historical and forecasted epidemiology, the pipeline insight as well as the Secondary Hyperparathyroidism market size and shares analysis in the seven major markets (7MM).
The report also covers emerging drugs, current treatment practices, Secondary Hyperparathyroidism Market Shares of the individual therapies, a detailed current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assess the underlying potential of the market.
The report analyses the Secondary Hyperparathyroidism Market trends and developments in the seven major markets (i.e. the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.
Secondary Hyperparathyroidism Market Key Facts
- As per the study conducted by Vijayadershan Muppidi et al. (2020), about 50% of the world population is affected by vitamin D insufficiency. CKD affects about 15% of the population in the U.S. In chronic kidney disease (CKD), increased PTH levels are seen, and there is a strong correlation between the prevalence and stage of CKD with increasing prevalence in advanced CKD.
- There were identified 32,971 parathyroidectomies for secondary hyperparathyroidism between 2002 and 2011. The overall rate of parathyroidectomy was approximately 5.4/1000 patients (95% confidence interval [95% CI], 5.0/1000 to 6.0/1000) [As per the study conducted by Sun Moon Kim et al. (2016)].
Secondary Hyperparathyroidism Market Growth
The Secondary Hyperparathyroidism market size is anticipated to increase in the coming years owing to the rise in the number of prevalent cases in 7MM.
The Secondary Hyperparathyroidism market analysis section of the report helps to understand the current and forecasted Secondary Hyperparathyroidism Market Trends and Growth by evaluating the impact of current therapies on the market, unmet needs, drivers, and barriers. The report gives complete detail of Secondary Hyperparathyroidism Market Size and Shares of each marketed drug and late-tage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Secondary Hyperparathyroidism Therapeutics Market
The pipeline for Secondary Hyperparathyroidism (SHPT) involves exciting new therapies and expanded trials of already approved drugs. Due to the emergence of calcimimetics and a better understanding of the strengths and limitations of native and active vitamin D compounds, the treatment options for patients with SHPT have improved.
Globally, some of the prominent companies are developing therapies for the treatment of patients with Secondary Hyperparathyroidism. The expected launch of emerging therapies is expected to change the Secondary Hyperparathyroidism treatment scenario in the upcoming years.
Some of the key companies in the Secondary Hyperparathyroidism market include TaiRx, PKO Health, Sanwa Kagaku Kenkyusho), and many others. Secondary Hyperparathyroidism Therapies covered in the report include SK-1403, TRX 711, CTAP101 (calcifediol) ER Capsules, CYP24A1 inhibitors, and many more.
Secondary Hyperparathyroidism Epidemiology Forecast
Secondary Hyperparathyroidism Epidemiology Segmentation
Prevalent Cases of Secondary Hyperparathyroidism
Diagnosed Cases of Secondary Hyperparathyroidism
Treatable Cases of SecondaryHyperparathyroidism
The epidemiology section covers detailed insights about the patient pool for every seven major countries. It helps to recognize the causes of current and forecasted Secondary Hyperparathyroidism Epidemiology Trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
For more details, visit: Secondary Hyperparathyroidism Market Growth